Pinatuzumab Vedotine (CD22) - Onderzoeksklasse Biosimilar
Gecertificeerd

Pinatuzumab Vedotine (CD22) - Onderzoeksklasse Biosimilar

Catalog #: 10-588
Maat: 0.1 mg

Kwaliteit

ISO Gecertificeerd

Levering

24-48 uur

Prijs -1%
Login voor prijs
BTW niet inbegrepen
Gratis verzending vanaf €100
Technische Documentatie

Technische Specificaties

Background

Pinatuzumab vedotin is under investigation in clinical trial NCT01691898, A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) .

Immunogen

Humanized / CD22 [Homo sapiens]

Clonality

• Recombinant Monoclonal

Conjugation

Unconjugated

Type

Primary Antibodies, Biosimilars

Source

CHO cells

Field of Research

Cancer

Purification

>95%

Concentration

Batch dependent

Buffer

PBS buffer pH7.5

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.

Fragment

IgG1-kappa

NCBI Organism

Homo sapiens

Other Product Names

ACD22-VCMMAE, DCDT2980S, FCU2803, RG-7593, RO5541072-000

Beschrijving

Pinatuzumab Vedotine (CD22) - Onderzoeksklasse Biosimilar Beschikbaar in 0.1 mg. Bestel eenvoudig online met snelle levering.

Specificaties

ProductnaamPinatuzumab Vedotine (CD22) - Onderzoeksklasse Biosimilar
Categorie
Beschikbare grootte0.1 mg
Catalogusnummer10-588